1. Scrip
  2. >>Conferences

ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data

 
• By Alaric DeArment

Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.

Merck stand at ASCO 2024
• Source: Scrip

Merck & Co., Inc. sees the individualized neoantigen therapy mRNA-4157, also known as V940, as a key pillar in its oncology development strategy over the next several years, which it said could deliver incremental sales of $20bn by the middle of the next decade, particularly after the presentation of positive follow-up data at the American Society of Clinical Oncology annual meeting.

Merck and partner Moderna, Inc. presented three-year data from the Phase II KEYNOTE-942 study of V940 combined with Keytruda...

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.